Elanco Animal Health Proposes Governance Enhancements in Proxy Statement

Ticker: ELAN · Form: DEF 14A · Filed: Apr 19, 2024 · CIK: 1739104

Elanco Animal Health Inc DEF 14A Filing Summary
FieldDetail
CompanyElanco Animal Health Inc (ELAN)
Form TypeDEF 14A
Filed DateApr 19, 2024
Risk Level
Pages15
Reading Time17 min
Key Dollar Amounts$100 million, $76 million, $1.3 b, $500 million
Sentimentbullish

Sentiment: bullish

Topics: governance, shareholder rights, proxy statement, board of directors, Elanco Animal Health

TL;DR

<b>Elanco Animal Health is proposing significant governance changes to enhance shareholder rights and accountability.</b>

AI Summary

Elanco Animal Health Inc (ELAN) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Elanco Animal Health is seeking shareholder approval for governance enhancements including declassifying the Board of Directors. The company proposes adopting a majority vote standard for uncontested director elections. Shareholders may be allowed to amend the Company's Bylaws under the proposed changes. The Board is also proposing to allow shareholders to call special meetings under certain circumstances. Elanco's Board engaged with investors representing approximately 50% of outstanding shares in the past year.

Why It Matters

For investors and stakeholders tracking Elanco Animal Health Inc, this filing contains several important signals. These proposed changes, including board declassification and majority voting standards, aim to align Elanco's governance with best practices and shareholder expectations. The company's proactive engagement with investors representing half of its outstanding shares suggests a commitment to incorporating shareholder feedback into its strategic direction.

Risk Assessment

Risk Level: — Elanco Animal Health Inc shows moderate risk based on this filing. The filing is a routine proxy statement detailing proposed governance changes, with no immediate negative financial or operational indicators presented.

Analyst Insight

Shareholders should carefully review the proposed governance changes, particularly those related to board declassification and shareholder rights to call special meetings, and vote accordingly.

Key Numbers

  • 50% — Shareholder Engagement (Investors representing approximately 50% of outstanding shares engaged with the Board.)

Key Players & Entities

  • Elanco Animal Health Inc (company) — Registrant name
  • Lawrence E. Kurzius (person) — Selected to be the next Chairman

FAQ

When did Elanco Animal Health Inc file this DEF 14A?

Elanco Animal Health Inc filed this Proxy Statement (DEF 14A) with the SEC on April 19, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Elanco Animal Health Inc (ELAN).

Where can I read the original DEF 14A filing from Elanco Animal Health Inc?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Elanco Animal Health Inc.

What are the key takeaways from Elanco Animal Health Inc's DEF 14A?

Elanco Animal Health Inc filed this DEF 14A on April 19, 2024. Key takeaways: Elanco Animal Health is seeking shareholder approval for governance enhancements including declassifying the Board of Directors.. The company proposes adopting a majority vote standard for uncontested director elections.. Shareholders may be allowed to amend the Company's Bylaws under the proposed changes..

Is Elanco Animal Health Inc a risky investment based on this filing?

Based on this DEF 14A, Elanco Animal Health Inc presents a moderate-risk profile. The filing is a routine proxy statement detailing proposed governance changes, with no immediate negative financial or operational indicators presented.

What should investors do after reading Elanco Animal Health Inc's DEF 14A?

Shareholders should carefully review the proposed governance changes, particularly those related to board declassification and shareholder rights to call special meetings, and vote accordingly. The overall sentiment from this filing is bullish.

How does Elanco Animal Health Inc compare to its industry peers?

Elanco Animal Health operates in the pharmaceutical preparations industry, focusing on animal health products.

Are there regulatory concerns for Elanco Animal Health Inc?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs proxy solicitations.

Risk Factors

  • Proxy Statement Filing [low — regulatory]: The filing is a Schedule 14A (DEF 14A) proxy statement, indicating a routine disclosure process.

Industry Context

Elanco Animal Health operates in the pharmaceutical preparations industry, focusing on animal health products.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs proxy solicitations.

What Investors Should Do

  1. Review the specific details of the proposed governance enhancements in the proxy statement.
  2. Evaluate the implications of board declassification and majority voting standards for shareholder influence.
  3. Consider Elanco's engagement with shareholders and how these proposals reflect that feedback.

Key Dates

  • 2024-04-19: Filing Date — Definitive Proxy Statement filed
  • 2024-05-30: Period of Report — Conformed period for the proxy statement

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (This filing type indicates Elanco is providing detailed information to shareholders for an upcoming meeting.)
Board Declassification
A process where directors serve fixed, staggered terms, moving towards all directors being elected annually. (This change would allow shareholders to vote on all directors each year, increasing accountability.)
Majority Vote Standard
A director must receive more 'for' votes than 'against' votes in uncontested elections. (This standard enhances director accountability to shareholders.)

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine proxy statement. No direct comparison to a prior filing's financial or operational data is available within this document.

Filing Stats: 4,362 words · 17 min read · ~15 pages · Grade level 17.8 · Accepted 2024-04-19 08:00:46

Key Financial Figures

  • $100 million — anticipated annual revenue of more than $100 million over time, that are expected to enter t
  • $76 million — te bonus program. In 2023, we paid down $76 million in gross debt and finished the year wit
  • $1.3 b — to divest our aquaculture business for $1.3 billion, approximately 7.4x the estimated
  • $500 million — by Novocure revenue growth of more than $500 million and adjusted EBITDA growth by hundreds

Filing Documents

Executive Compensation Tables

Executive Compensation Tables 71 Appendix E - Proposed Amendments to Articles of Incorporation (Proposal No. 7) E- 1 Pay Versus Performance 82 Proxy Statement Summary WAYS TO VOTE Online Prior to the Annual Meeting You may vote by proxy by visiting www.proxyvote.com and entering the control number found on your Notice of Internet Availability. Online During the Annual Meeting You may vote online during the Annual Meeting by visiting www.virtualshareholder meeting.com/ELAN2024 Telephone If you request printed copies of the proxy materials by mail, you will receive a proxy card or voting instruction form and you may vote by proxy by calling the toll-free number found on the card or form. Mail If you request printed copies of the proxy materials by mail, you will receive a proxy card or voting instruction form. This summary highlights information contained in this Proxy Statement. This summary does not contain all of the information that you should consider and you should carefully read the entire Proxy Statement before voting. Voting Matters and Recommendations Item of Business Board Recommendation Page 1 Election of four director nominees to serve three-year terms. "FOR" Each Nominee 9 2 Ratification of the appointment of Ernst & Young LLP as Elanco's independent registered public accounting firm for 2024. "FOR" 47 3 Advisory vote on the compensation of Elanco's named executive officers. "FOR" 50 4 Management proposal to amend Elanco's Articles of Incorporation to declassify the Board of Directors. "FOR" 87 5 Management proposal to amend Elanco's Articles of Incorporation to adopt a majority vote standard for uncontested elections of directors. "FOR" 89 6 Management proposal to amend Elanco's Articles of Incorporation to provide shareholders with the right to amend our Bylaws. "FOR" 91 7 Management proposal to amend Elanco's Articles of Incorporation to provide shareholders with the right to reques

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.